Gregg Owen Lehman Sells 8,889 Shares of InfuSystem Holdings, Inc. (NYSEAMERICAN:INFU) Stock

InfuSystem Holdings, Inc. (NYSEAMERICAN:INFUGet Rating) Director Gregg Owen Lehman sold 8,889 shares of the business’s stock in a transaction on Thursday, September 8th. The shares were sold at an average price of $7.75, for a total transaction of $68,889.75. Following the sale, the director now directly owns 346 shares in the company, valued at $2,681.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Gregg Owen Lehman also recently made the following trade(s):

  • On Monday, September 12th, Gregg Owen Lehman sold 1,900 shares of InfuSystem stock. The shares were sold at an average price of $7.88, for a total transaction of $14,972.00.
  • On Friday, June 17th, Gregg Owen Lehman sold 30,000 shares of InfuSystem stock. The shares were sold at an average price of $8.83, for a total transaction of $264,900.00.

InfuSystem Trading Down 0.5 %

InfuSystem stock opened at $7.62 on Tuesday. The company’s fifty day simple moving average is $8.74 and its 200-day simple moving average is $9.12. The company has a quick ratio of 1.25, a current ratio of 1.51 and a debt-to-equity ratio of 0.66. InfuSystem Holdings, Inc. has a 12 month low of $6.78 and a 12 month high of $19.14. The stock has a market cap of $157.70 million, a P/E ratio of 14.11 and a beta of 1.08.

InfuSystem (NYSEAMERICAN:INFUGet Rating) last posted its quarterly earnings results on Thursday, August 4th. The medical instruments supplier reported ($0.01) EPS for the quarter. The company had revenue of $27.04 million for the quarter. InfuSystem had a net margin of 11.64% and a return on equity of 26.77%. As a group, sell-side analysts forecast that InfuSystem Holdings, Inc. will post 0.05 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of InfuSystem from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 7th.

Institutional Investors Weigh In On InfuSystem

A number of large investors have recently bought and sold shares of the business. Wasatch Advisors Inc. boosted its holdings in InfuSystem by 18.6% in the first quarter. Wasatch Advisors Inc. now owns 859,679 shares of the medical instruments supplier’s stock worth $8,425,000 after purchasing an additional 135,076 shares in the last quarter. Vanguard Group Inc. boosted its holdings in InfuSystem by 8.6% in the first quarter. Vanguard Group Inc. now owns 859,052 shares of the medical instruments supplier’s stock worth $8,418,000 after purchasing an additional 68,242 shares in the last quarter. Meros Investment Management LP boosted its holdings in InfuSystem by 6.4% in the second quarter. Meros Investment Management LP now owns 520,116 shares of the medical instruments supplier’s stock worth $5,009,000 after purchasing an additional 31,311 shares in the last quarter. Ranger Investment Management L.P. boosted its holdings in InfuSystem by 24.7% in the fourth quarter. Ranger Investment Management L.P. now owns 484,636 shares of the medical instruments supplier’s stock worth $8,253,000 after purchasing an additional 95,954 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in InfuSystem by 8.7% in the first quarter. Renaissance Technologies LLC now owns 443,909 shares of the medical instruments supplier’s stock worth $4,350,000 after purchasing an additional 35,400 shares in the last quarter. 57.61% of the stock is currently owned by institutional investors.

InfuSystem Company Profile

(Get Rating)

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.

Featured Articles

Insider Buying and Selling by Quarter for InfuSystem (NYSEAMERICAN:INFU)

Receive News & Ratings for InfuSystem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InfuSystem and related companies with MarketBeat.com's FREE daily email newsletter.